Septin-5 Antibody, Cell Binding Assay, Serum
Use
Detecting septin-5 IgG by cell-binding assay using serum specimens. Septin-5 IgG is a biomarker of a rapidly progressive, but treatable, form of autoimmune cerebellar ataxia. Patients present with subacute onset of cerebellar ataxia with prominent eye movement symptoms (oscillopsia or vertigo). Improvement may occur after immunotherapy. Seropositivity for septin antibodies by indirect immunofluorescence is consistent with a diagnosis of autoimmune disease of the central nervous system. Cell-binding assay (CBA) testing for septin-5 IgG is required to confirm the diagnosis.
Special Instructions
Only orderable as a reflex test. This requires prior indication through indirect immunofluorescence testing patterns. For further details, refer to MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum. Ensure correct specimen volume and container type are used to avoid rejection.
Limitations
Negative results for septin-5 IgG by cell-binding assay do not exclude neurological autoimmunity or cancer. The assay does not have FDA clearance but is consistent with CLIA requirements. Gross hemolysis, lipemia, or icterus can lead to specimen rejection, affecting result reliability.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 101463-8
- 101463-8
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
Not provided
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial. Use a red top or serum gel container for collection.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |